2nd Annual Next Generation Sequencing Congress Asia
01 October 2012 - 02 October 2012
Next Generation Sequencing Asia Congress is to be held on the 3rd and 4th of October in Singapore. Over the 2 days, the conference will provide an overview of the current options of next-generation sequencing platforms, technologies, applications and the newest computational tools for the analysis of next-generation sequencing data and analytical genomics as well as overcoming data management problems.
Concorde Hotel Singapore
http://www.ngsasia-congress.com/
GPCR-based Drug Discovery. Progressing through Signalling Complexities
01 October 2012 - 02 October 2012
The GPCR program will continue its tradition of combining theory with screening and optimization strategies illustrated by case studies of drug candidates in development. Topics to be covered at this year’s meeting will include exploiting ligand-biased signaling; receptor desensitization, internalization and recycling in the context of developing drug candidates; new tools and technologies (functional screens, label-free assays); drug discovery Implications of recent GPCR crystal structures ; structure-based design strategies and therapeutic antibodies.
Copley Marriott Hotel, Boston MA, USA
http://www.discoveryontarget.com/GPCR-BasedDrugDiscovery
The importance of (Bio)Pharmaceutical properties in successful drug design
04 October 2012
National Heart & Lung Institute (NHLI), Kensington, London, UK
http://www.smr.org.uk/smr/default.asp
Orphan Drugs & Rare Diseases
08 October 2012 - 09 October 2012
Innovative strategies for getting orphan drugs to where they are needed...
The call to treat rare diseases has become louder around the world in recent years than ever before. Supportive organisations including patient groups, national health authorities, health trusts, academia, HTAs, pharmaceutical and biotechnical companies are now progressively growing in number and sophistication in their approaches to medicinal care for those with rare and ultra-rare diseases. This conference will present briefings from key opinion leaders, those with hands-on experience of regulating new drug discoveries, companies who have already developed advanced orphan drugs & successfully been granted orphan medicine status and selected experts in the field. Speakers will offer unique insights into cutting-edge international developments taking place in: expanding the reach of medicine to previously untreatable and unreachable patients with rare diseases; different regulatory and policy environments; new drug discoveries; innovative business strategies & funding & financing models, and the importance of partnerships with patient groups and those at the point-of-care.
Pharmaceutical companies, biotechnology companies, academic research units and other stakeholders organisations are increasingly merging their research, resources and expertise in the critical process of discovering new biopharmaceutical therapies to improve the lives of rare disease sufferers. Orphan Drugs & Rare Diseases will provide an exclusive opportunity to network with these leading experts on not only rare diseases research but ultra-rare diseases and the medicinal solutions currently being invented to treat them.
SMi's symposium will demonstrate innovative models for translational research; the global economic environment for orphan drugs; how to bring your orphan drugs to the patient and to market successfully and other key business strategies that companies must consider when entering and working in the orphan drugs field.
Attend to hear perspectives from rare diseases trusts, patient groups, regulators & HTAs, academia, pharmaceutical and biotechnology companies as they give presentations on: health technology appraisals & market access; the process of achieving orphan drug status; reimbursement, and new patient treatments.
The Copthorne Tara Hotel, London, UK
http://www.smi-online.co.uk/events/overview.asp?is=4&ref=4016&utm_source=P-076&utm_medium=EM%20-%20PM&utm_campaign=GroupMail
Pharmaceutical Flow Cytometry & Imaging 2012
10 October 2012 - 11 October 2012
We are happy to announce the dates for the 3rd Pharmaceutical Flow Cytometry & Imaging meeting, to be held at the AstraZeneca Conference Centre, AstraZeneca R&D Alderley Park, UK, on the 10th & 11th October 2012. This meeting continues to be the ideal forum for users of Flow Cytometry & Imaging Systems within drug discovery and drug development to get together, share expertise and innovation, discuss pitfalls, successes and future directions.
Following on from the great success and positive feedback from our previous meetings, we are continuing to include topics of current interest by adding Phenotypic Screening and Personalised Health Care to the areas that will be addressed. Typical attendees will be colleagues from small-to mid-sized biotech companies, contract research organisations and global pharmaceutical companies. The content of this free two day meeting will also include other industrial-based themes covering the drug development journey from discovery to clinical evaluation.
AstraZeneca R&D, Alderley Park, UK
http://elrig.org/
2nd Oncology Biomarkers Congress
10 October 2012 - 11 October 2012
Oxford Global is proud to present the 2nd Oncology Biomarkers Congress to be held on the 10th -11th October 2012, Manchester. It is to be co-located with our Oncology Clinical Development Congress.
Hilton Deansgate Hotel, Manchester, UK
http://www.oncologybiomarkers-congress.com/
22nd Neuropharmacology Conference: Cognitive Enhancers
11 October 2012 - 12 October 2012
Cognitive enhancement has become a subject of considerable research and, both in neuroscience and society at large, growing controversy. This satellite meeting will survey progress in the field from attempts to facilitate the substrates of memory and cognition in animal models to clinical studies targeted at major psychiatric disorders. Attendees will accordingly have a first-hand opportunity to learn about the broad spectrum of enhancement research ranging from epigenetics through synaptic plasticity and brain networks to behavior.
Hilton Riverside, New Orleans, LA, USA
http://www.neuropharmacology-conference.elsevier.com/
EMBO | EMBL Symposium: Germline - Immortality through Totipotency
13 October 2012 - 16 October 2012
This EMBO | EMBL Symposium will go beyond a description of the phenomena involving stem cell behaviour, programming and reprogramming. It will bring together researchers from different disciplines, who will address fundamental questions of totipotency as they relate to evolution, development and tissue specialization.
EMBL Advanced Training Centre Heidelberg, Germany
http://www.embo-embl-symposia.org/symposia/2012/EES12-04/
6th Vaccine and ISV course
14 October 2012 - 16 October 2012
The 6th Vaccine and ISV Congress will feature science and public health topics, from primary vaccine research and vaccine manufacturers, to governmental policy, safety and regulation. If you work as a researcher in vaccine-related topics, in the vaccine industry, or in vaccine policy making, make sure you attend this important event which is taking place in China for the first time in its history.
Shanghai Marriott Hotel City Centre, Shanghai, China
http://www.vaccinecongress.com/
New Paradigms in Drug Discovery: Challenges and Opportunities in Africa
15 October 2012 - 18 October 2012
Vineyard Hotel, Newlands, Cape Town, South Africa
http://www.h3-d.uct.ac.za/
Pharma Anti-Counterfeiting 2012
18 October 2012
This conference will gather government bodies, pharmaceutical companies and solution and technology providers to discuss the in-depth insights into the strategies and cutting edge technologies for pharmaceutical anti-counterfeiting.
London Marriott Marble Arch Hotel, London, UK
http://www.virtueinsight.com/pharma/Pharma-Anti-Counterfeiting-2012/
COPD: Novel Therapeutics & Management Strategies
22 October 2012 - 23 October 2012
This conference continues to promote increased awareness of COPD and explores ways to improve quality of life for patients, prevention of exacerbations and analyses the new treatment techniques developed over the previous twelve months.
SMi's 4th annual conference on COPD will provide attendees with a complete view of the field and will focus on novel combination therapies, the latest insights in drug developments and clinical trial design, as well as discussing health economics of COPD drugs, this informative event will bring together key opinion leaders in the field to provide attendees with an in-depth look into current advances in COPD.
Copthorne Tara Hotel, London, UK
http://www.smi-online.co.uk/events/overview.asp?is=4&ref=4072
4th Translational Medicine Conference
24 October 2012 - 26 October 2012
This meeting will bring together representatives from Pharma, government and leading academic institutions to cover a range of issues facing the field of translational science. Topics of discussion will include target identification and validation, predictive safety and toxicology, translation of animal models and the development of predictive preclinical models. Additionally, industry focused topics in biomarker development such as companion diagnostics for personalized medicine and industry-academic collaborations will be discussed.
Pennsylvania Convention Center, Philadelphia, PA, USA
http://www.gtcbio.com/index.php?option=com_conference&file=home&cn=4th%20Translational%20Medicine&cid=102
9th Stem Cell Research & Therapeutics Conference
24 October 2012 - 26 October 2012
This forum presents information regarding cutting-edge developments in all areas of stem cell research including the biology, medicine, applications and regulations of stem cells. Recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, stem cell reprogramming, and regulatory policies regarding stem cell research will be addressed.
tbc Philadelphia, PA, USA
http://www.gtcbio.com/component/conference/?file=home&cn=9th+Stem+Cell+Research+&Therapeutics_Conference=&cid=71
8th Modern Drug Discovery & Development Summit
24 October 2012 - 26 October 2012
Over 125 leading industry and academic experts will speak at this three-day summit. The M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need.
Dedicated networking events have been incorporated to enhance the exchange of information between technology developers and end-users. The M3D will provide a great opportunity for companies to expose products and services.
Pennsylvania Convention Center, Philadelphia, PA, USA
http://www.gtcbio.com/index.php?option=com_conference&file=home&cn=8th%20Modern%20Drug%20Discovery%20&cid=47
International Conference on Juvenile Myoclonic Epilepsy
26 October 2012 - 28 October 2012
Patients with Juvenile Myoclonic Epilepsy – or Janz Syndrome – still face suboptimal management due to uncertainty about the criteria, treatment in the different age groups, and lifestyle recommendations worldwide recognition of the condition. However, in the past five years many studies in Juvenile Myoclonic Epilepsy patients have provided crucial new insights. Discover what these will mean for the future of JME, at the International Conference on Juvenile Myoclonic Epilepsy at the Bel Air Hotel, The Hague, The Netherlands on October 26th – 28th 2012.
Bel Air Hotel, The Hague, The Netherlands
http://www.juvenile-myoclonic-epilepsy.com/
11th Annual Biosimilars UK
29 October 2012 - 31 October 2012
Visiongain’s Biosimilars event will provide a unique networking event to boost your understanding of how to:
• Review the latest regulatory guidelines and understand how it will affect you and your competitors
• Assess the financial viability of manufacturing biosimilars and explore alternative pathways for approval
• Learn how to incorporate a patent portfolio strategy to prepare for the changing landscape
• Explore strategies to overcome legal issues to gain marketing approval
• Analyse preclinical and clinical challenges in proving interchangeability and patient saf! ety
• Gain insight into the role the US and European market will ha ve in developing biosimilars
• Investigate pricing and re-imbursement plans especially for meeting government healthcare demands
• Plan a pharmacovigilance framework to monitor patient safety
• Utilise a great networking opportunity with key players in the market
London EC1, UK
http://www.visiongain.com/Conference/339/11th-Annual-Biosimilars-UK
Molecular Interactions in Biopharmaceutical Formulations: Can Stability be Rationalised and Predicted?
30 October 2012
Formulation of biotherapeutics, leading to the development of stable and convenient drug products, is a crucial part of the biopharmaceutical process. The stability of biological molecules depends on a complex set of molecular interactions; understanding these interactions is critical for the success of the formulation development. MiBio 2012 will gather world leading experts from academia and from industry to take us from theoretical predictions of protein behaviour, through probing molecular interactions all the way to solving specific formulation issues of drug product candidates. The meeting will be interactive and whether you are a formulation scientist, process development scientist or an academic with interest in molecular interactions, we are convinced that you find this event extremely interesting and useful.
Trinity Centre, Cambridge, UK
http://www.formulation.org.uk/mibio-2012.html